CareDx, Inc. 8-K

What Happened

• CareDx, Inc. announced on April 15, 2026 that it entered into a Purchase Agreement to sell the shares of CareDx AB (its wholly owned Swedish subsidiary) and certain assets related to its kitted laboratory products business and related software to Eurobio Scientific S.A. for $170 million in cash, subject to customary working capital, cash and indebtedness adjustments. The transaction is conditioned on customary closing requirements, including regulatory approval and the absence of a continuing material adverse effect on the Business. CareDx also furnished a press release with preliminary unaudited financial results for the quarter ended March 31, 2026.

Key Details

• Purchase price: $170 million in cash, subject to customary post-closing adjustments (working capital, cash, indebtedness).
• Agreement date: April 15, 2026; outside termination date if not closed: October 15, 2026.
• Closing conditions/rights: subject to representations and warranties, covenants, required regulatory approvals; includes customary termination rights (mutual consent, illegality, uncured material breach, material adverse effect).
• Commercial/transition terms: parties will enter a transition services agreement at closing. CareDx gets exclusive distribution rights in the U.S., Canada and Mexico for Eurobio-manufactured NGS- and PCR-based post‑transplant assays (e.g., AlloSeqcfDNA, AlloSeqHCT); Eurobio may continue serving its pre‑closing customers and retains limited exclusive rights to sell the current CareDx chimerism assay to CareDx’s existing customers in North America for three years.

Why It Matters

• The sale represents a strategic divestiture of CareDx’s kitted lab products business and could materially change the company’s product mix and future revenue composition; proceeds (~$170M before adjustments) may affect CareDx’s cash position and capital allocation.
• The deal is subject to regulatory approval and closing conditions, so it is not final until those are met. Investors should review the Purchase Agreement and the April 15, 2026 press release (Exhibit 99.1) for the company’s preliminary Q1 2026 financial metrics and for any additional details on timing, adjustments and transitional arrangements.